CDK4 and non-small cell lung carcinoma: Owing to the unsatisfactory results of single-drug treatments, in-depth study of the pathogenesis of NSCLC, and increasing treatment methods for NSCLC, combinations of CDK4/6 inhibitors have been extensively studied.